Marga Teulen

410 total citations
12 papers, 290 citations indexed

About

Marga Teulen is a scholar working on Infectious Diseases, Pharmacology and Epidemiology. According to data from OpenAlex, Marga Teulen has authored 12 papers receiving a total of 290 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Infectious Diseases, 4 papers in Pharmacology and 4 papers in Epidemiology. Recurrent topics in Marga Teulen's work include HIV/AIDS drug development and treatment (5 papers), Antibiotics Pharmacokinetics and Efficacy (4 papers) and Tuberculosis Research and Epidemiology (3 papers). Marga Teulen is often cited by papers focused on HIV/AIDS drug development and treatment (5 papers), Antibiotics Pharmacokinetics and Efficacy (4 papers) and Tuberculosis Research and Epidemiology (3 papers). Marga Teulen collaborates with scholars based in Netherlands, United States and Indonesia. Marga Teulen's co-authors include Rob E. Aarnoutse, David M. Burger, Daan J. Touw, Nielka P. van Erp, Gerjo J. de Knegt, Jurriaan E.M. de Steenwinkel, Dick van Soolingen, Martin J. Boeree, Marian T. ten Kate and Irma A. J. M. Bakker‐Woudenberg and has published in prestigious journals such as American Journal of Respiratory and Critical Care Medicine, Antimicrobial Agents and Chemotherapy and AIDS.

In The Last Decade

Marga Teulen

12 papers receiving 286 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marga Teulen Netherlands 8 179 78 70 49 37 12 290
Hadija Semvua Tanzania 12 267 1.5× 172 2.2× 54 0.8× 51 1.0× 37 1.0× 26 376
Jason Seet Australia 8 162 0.9× 72 0.9× 82 1.2× 48 1.0× 23 0.6× 12 361
Neesha Rockwood United Kingdom 12 281 1.6× 160 2.1× 40 0.6× 61 1.2× 44 1.2× 24 406
Linda M. Spooner United States 14 192 1.1× 170 2.2× 34 0.5× 32 0.7× 43 1.2× 27 418
Naoya Okumura Japan 9 159 0.9× 45 0.6× 31 0.4× 66 1.3× 63 1.7× 17 331
Yoninah Cramer United States 9 211 1.2× 130 1.7× 27 0.4× 29 0.6× 44 1.2× 17 345
E.C.M. van Gorp Netherlands 9 262 1.5× 50 0.6× 65 0.9× 22 0.4× 44 1.2× 9 511
Roeland E. Wasmann South Africa 14 230 1.3× 124 1.6× 166 2.4× 21 0.4× 42 1.1× 40 403
Patricia K. Mydlow United States 6 205 1.1× 131 1.7× 27 0.4× 40 0.8× 33 0.9× 7 367
Wael A. Alghamdi Saudi Arabia 12 186 1.0× 131 1.7× 118 1.7× 44 0.9× 61 1.6× 26 337

Countries citing papers authored by Marga Teulen

Since Specialization
Citations

This map shows the geographic impact of Marga Teulen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marga Teulen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marga Teulen more than expected).

Fields of papers citing papers by Marga Teulen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marga Teulen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marga Teulen. The network helps show where Marga Teulen may publish in the future.

Co-authorship network of co-authors of Marga Teulen

This figure shows the co-authorship network connecting the top 25 collaborators of Marga Teulen. A scholar is included among the top collaborators of Marga Teulen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marga Teulen. Marga Teulen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
2.
Teulen, Marga, et al.. (2021). Highly sensitive quantification of pemetrexed in human plasma using UPLC‐MS/MS to support microdosing studies. Biomedical Chromatography. 36(2). e5277–e5277. 5 indexed citations
3.
Brüggemann, Roger J. M., et al.. (2020). First international quality control programme for laboratories measuring antimicrobial drugs to support dose individualization in critically ill patients. Journal of Antimicrobial Chemotherapy. 76(2). 430–433. 9 indexed citations
4.
Feiterna‐Sperling, Cornelia, et al.. (2020). Low raltegravir transfer into the breastmilk of a woman living with HIV. AIDS. 34(12). 1863–1865. 1 indexed citations
5.
6.
7.
Rijnders, Bart, et al.. (2016). Dolutegravir is not removed during hemodialysis. AIDS. 30(9). 1490–1491. 7 indexed citations
8.
Yunivita, Vycke, Sofiati Dian, Ahmad Rizal Ganiem, et al.. (2016). Pharmacokinetics and safety/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients. International Journal of Antimicrobial Agents. 48(4). 415–421. 43 indexed citations
9.
Schalkwijk, Stein, Rick Greupink, Angela Colbers, et al.. (2015). Placental transfer of the HIV integrase inhibitor dolutegravir in anex vivohuman cotyledon perfusion model. Journal of Antimicrobial Chemotherapy. 71(2). 480–483. 29 indexed citations
10.
Brake, Lindsey H. M. te, Rovina Ruslami, Fieke Mooren, et al.. (2015). Exposure to Total and Protein-Unbound Rifampin Is Not Affected by Malnutrition in Indonesian Tuberculosis Patients. Antimicrobial Agents and Chemotherapy. 59(6). 3233–3239. 18 indexed citations
11.
Steenwinkel, Jurriaan E.M. de, Rob E. Aarnoutse, Gerjo J. de Knegt, et al.. (2013). Optimization of the Rifampin Dosage to Improve the Therapeutic Efficacy in Tuberculosis Treatment Using a Murine Model. American Journal of Respiratory and Critical Care Medicine. 187(10). 1127–1134. 67 indexed citations
12.
Burger, David M., et al.. (2011). The International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma: A Global Proficiency Testing Program. Therapeutic Drug Monitoring. 33(2). 239–243. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hadija Semvua Breakdown of academic impact, for papers by Jason Seet Breakdown of academic impact, for papers by Neesha Rockwood Breakdown of academic impact, for papers by Linda M. Spooner Breakdown of academic impact, for papers by Naoya Okumura Breakdown of academic impact, for papers by Yoninah Cramer Breakdown of academic impact, for papers by E.C.M. van Gorp Breakdown of academic impact, for papers by Roeland E. Wasmann Breakdown of academic impact, for papers by Patricia K. Mydlow Breakdown of academic impact, for papers by Wael A. Alghamdi
Rankless by CCL
2026